Amber Sabbe

Amber Sabbe

Auto-generated profile, based on publicly available information

Amber Sabbe

Faculty of Medicine and Health Sciences, Endocrinology-Diabetology, Antwerp University Hospital and University of Antwerp , 2650 Edegem

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
ASAmber Sabbe
Amber Sabbe
NBNiels Bochanen
Niels Bochanen
ABAnnelies Van Den Broucke
Annelies Van Den Broucke
KMKatarina Mihaljčić
Katarina Mihaljčić
ABAxelle Bigaré
Axelle Bigaré
Christophe De BlockChristophe De Block
Christophe De Block
Context: Beyond HbA1c, continuous glucose monitoring (CGM) is now widely used in clinical practice, providing more detailed information about glycemic control. However, its ability to predict long-term microvascular outcomes in type 1 diabetes remains unclear. Objective: To evaluate the association between CGM-derived glucometrics and the 5-year incidence of microvascular complications, providing longitudinal real-world evidence in adults with type 1 diabetes. Design: Longitudinal real-world cohort study with 5-year follow-up. Setting: Tertiary referral center. Participants: Two hundred forty-six adults with type 1 diabetes (median age 40 [28-53] years, diabetes duration 24 [13-33] years). Intervention: No interventional treatment. Main Outcome Measure: Composite microvascular endpoint including nephropathy (persistent albuminuria ≥20 µg/min, estimated glomerular filtration rate <60 mL/min/1.73 m2, and/or renin–angiotensin–aldosterone system inhibitor use for albuminuria), severe retinopathy (proliferative retinopathy, maculopathy, and/or blindness), and peripheral neuropathy (monofilament score <6/6 and/or abnormal nerve conduction). Results: HbA1c decreased from 7.6% (59 mmol/mol) to 7.2% (55 mmol/mol), and time in range (TIR, 70-180 mg/dL) increased from 50 ± 14% to 61 ± 15%. All CGM-derived metrics (TIR, mean glucose, glucose management indicator) were associated with the composite endpoint. In this longitudinal real-world cohort, a ≥10% decrease in TIR was associated with higher complication rates (33.3%) compared with a stable TIR (7.9%) or ≥10% increase (15.0%) (P = .011). In multivariable analyses adjusted for age and baseline TIR, change in TIR (ΔTIR) remained independently associated with outcomes. Body mass index and systolic blood pressure were not significant. Models incorporating glucometrics and age showed acceptable discriminative performance (area under the curves 0.757-0.787). Conclusion: Continuous glucose monitoring–derived glucometrics were associated with the 5-year incidence of microvascular complications in this real-world cohort, with ΔTIR potentially providing additional prognostic information beyond glycated hemoglobin (HbA1c). Further validation is needed before routine clinical implementation.